← Back to Knowledge Base

Primary topic: TCF7L2 diabetes gene

TCF7L2 Gene and Metabolism: What It Means for Your Body

TCF7L2 is one of the better-known glucose-related genes and becomes relevant when insulin and carb-response questions need clearer prioritization.

What is the TCF7L2 gene?

TCF7L2 influences pathways related to glucose regulation and insulin dynamics. It is often discussed in the context of type 2 diabetes risk, but the practical value is in deciding whether glucose follow-up deserves more attention.

How TCF7L2 affects metabolism

If TCF7L2-related patterns are less favorable, glucose handling may be less forgiving over time. That matters even before disease labels become relevant, especially when symptoms and family context overlap.

What happens when TCF7L2 is altered

Altered TCF7L2 function does not determine outcome, but it can increase the importance of validating glucose-related markers rather than assuming everything is fine because symptoms are still vague.

Curated SNP evidence for TCF7L2

These SNPs come from the approved study-level evidence model. Each claim is scored from curated study rows, then gated before it can influence pathway scoring.

Glucose

Evidence-backed report connection

TCF7L2 currently has 2 curated SNPs, 6 claim-level scores, and 2 claims eligible for pathway scoring.

Open the sample report
rs12255372TCF7L2 supporting signal3 claims · 9 study rows

biomarker tendency · GT

TCF7L2 biomarker tendency

Not used for pathway scoring

rs12255372 GT is associated with increased TCF7L2 biomarker tendency.

TCF7L2 rs12255372 is scored as a modest glycemic-response biomarker tendency for T-containing genotypes, with a stronger score for TT than GT.

Likely effectHigher biomarker tendency
Signal sizeSmall signal
Evidence supportLimited support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data identify rs12255372 as a TCF7L2 intronic variant with common G and T alleles. This supports using GG, GT, and TT genotype letters for the simplified record.PMC3854403review · close proxyWang et al. performed a meta-analysis of rs12255372 in TCF7L2 and type 2 diabetes across 42 studies. The pooled results reported higher association estimates for the T allele, GT genotype, and TT genotype compared with GG, supporting a cautious allele-dose biomarker-tendency score.Evidence 3review · close proxyA large HuGE review and meta-analysis included rs12255372 as the TCF7L2 IVS4G>T polymorphism and reported higher type 2 diabetes association estimates for TT and GT genotypes compared with GG. This supports scoring T-containing genotypes but does not establish a direct enzyme, transporter, or single-biomarker effect.

biomarker tendency · TT

TCF7L2 biomarker tendency

Not used for pathway scoring

rs12255372 TT is associated with increased TCF7L2 biomarker tendency.

TCF7L2 rs12255372 is scored as a modest glycemic-response biomarker tendency for T-containing genotypes, with a stronger score for TT than GT.

Likely effectHigher biomarker tendency
Signal sizeSmall signal
Evidence supportLimited support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data identify rs12255372 as a TCF7L2 intronic variant with common G and T alleles. This supports using GG, GT, and TT genotype letters for the simplified record.PMC3854403review · close proxyWang et al. performed a meta-analysis of rs12255372 in TCF7L2 and type 2 diabetes across 42 studies. The pooled results reported higher association estimates for the T allele, GT genotype, and TT genotype compared with GG, supporting a cautious allele-dose biomarker-tendency score.Evidence 3review · close proxyA large HuGE review and meta-analysis included rs12255372 as the TCF7L2 IVS4G>T polymorphism and reported higher type 2 diabetes association estimates for TT and GT genotypes compared with GG. This supports scoring T-containing genotypes but does not establish a direct enzyme, transporter, or single-biomarker effect.

biomarker tendency · GG

TCF7L2 biomarker tendency

Not used for pathway scoring

rs12255372 GG has no scored directional claim for TCF7L2 biomarker tendency.

TCF7L2 rs12255372 is scored as a modest glycemic-response biomarker tendency for T-containing genotypes, with a stronger score for TT than GT.

Likely effectNo clear biomarker tendency
Signal sizeMinimal signal
Evidence supportVery limited support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data identify rs12255372 as a TCF7L2 intronic variant with common G and T alleles. This supports using GG, GT, and TT genotype letters for the simplified record.PMC3854403review · close proxyWang et al. performed a meta-analysis of rs12255372 in TCF7L2 and type 2 diabetes across 42 studies. The pooled results reported higher association estimates for the T allele, GT genotype, and TT genotype compared with GG, supporting a cautious allele-dose biomarker-tendency score.Evidence 3review · close proxyA large HuGE review and meta-analysis included rs12255372 as the TCF7L2 IVS4G>T polymorphism and reported higher type 2 diabetes association estimates for TT and GT genotypes compared with GG. This supports scoring T-containing genotypes but does not establish a direct enzyme, transporter, or single-biomarker effect.
rs7903146TCF7L2 primary signal3 claims · 12 study rows

biomarker tendency · TT

TCF7L2 biomarker tendency

Strong

rs7903146 TT is associated with increased TCF7L2 biomarker tendency.

TCF7L2 rs7903146 is scored as a glycemic-response biomarker tendency for T-containing genotypes, with a stronger score for TT than CT.

Likely effectHigher biomarker tendency
Signal sizeModerate signal
Evidence supportStrong support
Report useIncluded in pathway scoring
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data identify rs7903146 as a TCF7L2 intronic variant with common C and T alleles. This supports using CC, CT, and TT genotype letters for the simplified record.PubMed 25015099expression eqtl · loose proxyZhou et al. studied TCF7L2 in rodent and human pancreatic islets and reported that the rs7903146 risk T allele was associated with increased TCF7L2 expression, lower insulin content, and lower insulin secretion. This supports a positive biomarker-tendency score for T-containing genotypes, with stronger scoring for TT than CT.PubMed 32788279biomarker association · close proxyGalderisi et al. reported that the T risk allele at rs7903146 was associated with a reduced incretin effect in obese youth without diabetes, along with a higher 1-hour glucose peak and lower insulin secretion-related measures in the lower incretin-effect group. This supports a cautious glycemic-response tendency rather than a diagnosis.Evidence 4review · close proxyA large HuGE review and meta-analysis reported higher type 2 diabetes association estimates for rs7903146 TT and CT genotypes compared with CC across many studies. This supports allele-dose-aware scoring, while the record remains limited to biomarker tendency and not disease prediction.

biomarker tendency · CT

TCF7L2 biomarker tendency

Moderate

rs7903146 CT is associated with increased TCF7L2 biomarker tendency.

TCF7L2 rs7903146 is scored as a glycemic-response biomarker tendency for T-containing genotypes, with a stronger score for TT than CT.

Likely effectHigher biomarker tendency
Signal sizeSmall signal
Evidence supportStrong support
Report useIncluded in pathway scoring
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data identify rs7903146 as a TCF7L2 intronic variant with common C and T alleles. This supports using CC, CT, and TT genotype letters for the simplified record.PubMed 25015099expression eqtl · loose proxyZhou et al. studied TCF7L2 in rodent and human pancreatic islets and reported that the rs7903146 risk T allele was associated with increased TCF7L2 expression, lower insulin content, and lower insulin secretion. This supports a positive biomarker-tendency score for T-containing genotypes, with stronger scoring for TT than CT.PubMed 32788279biomarker association · close proxyGalderisi et al. reported that the T risk allele at rs7903146 was associated with a reduced incretin effect in obese youth without diabetes, along with a higher 1-hour glucose peak and lower insulin secretion-related measures in the lower incretin-effect group. This supports a cautious glycemic-response tendency rather than a diagnosis.Evidence 4review · close proxyA large HuGE review and meta-analysis reported higher type 2 diabetes association estimates for rs7903146 TT and CT genotypes compared with CC across many studies. This supports allele-dose-aware scoring, while the record remains limited to biomarker tendency and not disease prediction.

biomarker tendency · CC

TCF7L2 biomarker tendency

Not used for pathway scoring

rs7903146 CC has no scored directional claim for TCF7L2 biomarker tendency.

TCF7L2 rs7903146 is scored as a glycemic-response biomarker tendency for T-containing genotypes, with a stronger score for TT than CT.

Likely effectNo clear biomarker tendency
Signal sizeMinimal signal
Evidence supportVery limited support
Report useEvidence only, not scored
Show study evidence
NCBI RefSNP recordidentity only · unknownNCBI RefSNP data identify rs7903146 as a TCF7L2 intronic variant with common C and T alleles. This supports using CC, CT, and TT genotype letters for the simplified record.PubMed 25015099expression eqtl · loose proxyZhou et al. studied TCF7L2 in rodent and human pancreatic islets and reported that the rs7903146 risk T allele was associated with increased TCF7L2 expression, lower insulin content, and lower insulin secretion. This supports a positive biomarker-tendency score for T-containing genotypes, with stronger scoring for TT than CT.PubMed 32788279biomarker association · close proxyGalderisi et al. reported that the T risk allele at rs7903146 was associated with a reduced incretin effect in obese youth without diabetes, along with a higher 1-hour glucose peak and lower insulin secretion-related measures in the lower incretin-effect group. This supports a cautious glycemic-response tendency rather than a diagnosis.Evidence 4review · close proxyA large HuGE review and meta-analysis reported higher type 2 diabetes association estimates for rs7903146 TT and CT genotypes compared with CC across many studies. This supports allele-dose-aware scoring, while the record remains limited to biomarker tendency and not disease prediction.

Common symptoms people report

  • fatigue or brain fog after higher-carb meals
  • weight and glucose concerns clustering together
  • family context around diabetes risk
  • worry that routine glucose markers may deserve closer review

Biomarkers to validate

Fasting insulin

Useful early marker for glucose-regulation pressure.

HbA1c

Helpful for longer-term glucose exposure.

Fasting glucose

Basic but still relevant when viewed with insulin.

Where DNA analysis helps

DNA can show whether glucose-regulation pathways deserve more attention before symptoms and habits are reduced to generic diet talk.

Example Insight

Your glucose-regulation pathway may deserve earlier follow-up than generic wellness advice would suggest.

Suggested validation: fasting insulin and HbA1c.

What to do next

  • Check insulin and glucose markers together instead of one at a time.
  • Compare TCF7L2 with IRS1 and FTO when appetite and carb response overlap.
  • Use the signal to prioritize follow-up, not to assume a fixed future outcome.

Upload your DNA file and receive a structured metabolic pathway analysis with prioritized insights and suggested validation markers.

Get My DNA Report

Related pages

IRS1

IRS1 insulin signaling gene

FTO

FTO gene weight gain

Triglycerides

triglycerides and metabolic health

ApoB

ApoB and lipid risk

Glucose regulation pathway

glucose regulation pathway

Lipid transport pathway

lipid transport pathway

Genetic test for weight loss Europe

genetic test for weight loss Europe

Related symptom angle

Insulin resistance genetics

Browse the knowledge base

See the full index of gene guides, biomarker guides, pathway guides, symptoms, buyer pages, and common questions.